Michael L. Shelanski, MD, PhD

Departments And Divisions

  • Department of Pathology & Cell Biology
  • Delafield Professor of Pathology and Cell Biology (in Neuroscience and in the Taub Institute of Research on Alzheimer's Disease and the Aging Brain)
  • Senior Vice Dean for Research
Michael L. Shelanski, <span>MD, PhD</span>

We are using a combination of cell biological and molecular biological approaches, including anti-sense technology, to study the function of two proteins: the intermediate filament peripherin and the high molecular weight form of the microtubule associated protein tau. These proteins are characteristic of the cytoskeleton of the peripheral neuron. We are interested in why there are differences between the central and peripheral cytoskeleton and whether these differences are related to the greater regenerative potential of peripheral neurons. To aid in this effort we have set up a model "axon" using baculovirus expression and insect SF9 cells to assess interactions between specific cytoskeletal components. A related series of studies is investigating the mechanism by which astrocytes and neurons initiate the formation of long asymmetric processes. Our approach has shown that process formation in the astrocyte is inhibited by the cortical actin network and favored by the assembly of microtubules. This equilibrium is controlled by the myosin light chain kinase acting on the myosin light chain and on destrin, an actin-severing protein. These studies utilize a variety of cell biology approaches including biochemistry, EM, optical imaging and antisense oligonucleotides. Other research in the laboratory is on the role of cytokines, specifically IL-1, on the development of cytoskeletal changes in Alzheimer's disease.


    Education & Training

  • University of Chicago Pitzker School of Medicine
  • Residency: Jacobi Medical Center
  • Fellowship: University of Chicago Hospitals

Lab Locations

  • 630 West 168th Street
    P&S 15-402
    New York, NY 10032
    (212) 305-3300
    (212) 305-5498

Past Positions

  • 1978-1987: New York University School of Medicine
    Professor and Chairman, Department of Pharmacology Director, Medical Scientist Training Program
  • 1974-1978: Harvard Medical School
    Associate Professor of Neurology
    Assistant Pathologist and Senior Associate in Neuroscience, Children’s Hospital
  • 1973-1974: Institut Pasteur
    Visiting Scientist, Department of Molecular Biology (J-P Changeux)
  • 1971-1973: National Institutes of Health
    Staff Investigator, Laboratory of Biochemical Genetics (M. Nirenberg), NHLI
  • 1969-1971: Albert Einstein College of Medicine
    Assistant Professor of Pathology
  • 1967-1969: Albert Einstein College of Medicine
    Intern and Fellow in Neuropathology
  • 1966-1967: University of Chicago
    USPHS Postdoctoral Fellow in Biophysics

Honors & Awards

  • Alpha Omega Alpha
  • Teacher-Investigator Award, NINCDS, 1971-74
  • Guggenheim Foundation Fellow, 1973-1974
  • McKnight Scholar in Neurosciences 1977-84
  • Javits Neuroscience Investigator Award NINCDS 1994-2001
  • Association of American Physicians
  • Institute of Medicine. National Academy of Sciences

Research Interests

  • Cytoskeleton and Neural Development
  • Neural Degeneration and Repair


Aubry S, Shin W, Crary JF, Lefort R, Qureshi YH, Lefebvre C, Califano A, Shelanski ML. (2015) Assembly and interrogation of Alzheimer's disease genetic networks reveal novel regulators of progression. PloS one. 10(3):e0120352. doi: 10.1371/journal.pone.0120352.

Padmanabhan J, Brown KR, Padilla A, Shelanski ML. (2015) Functional role of RNA polymerase II and P70 S6 kinase in KCl withdrawal-induced cerebellar granule neuron apoptosis. The Journal of biological chemistry. 290:5267-79. doi: 10.1074/jbc.M114.575225.

Pasini S, Corona C, Liu J, Greene LA, Shelanski ML. (2015) Specific Downregulation of Hippocampal ATF4 Reveals a Necessary Role in Synaptic Plasticity and Memory. Cell Reports. 11:183-91.

Santa-Maria I, Alaniz ME, Renwick N, Cela C, Fulga TA, Van Vactor D, Tuschl T, Clark LN, Shelanski ML, McCabe BD, Crary JF. (2015) Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. The Journal of clinical investigation. 125:681-6. doi: 10.1172/JCI78421.

Shelanski M, Shin W, Aubry S, Sims P, Alvarez MJ, Califano A. (2015) A systems approach to drug discovery in Alzheimer's disease. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. 12:126-31. doi: 10.1007/s13311-014-0335-5.

Liu J, Pasini S, Shelanski ML, Greene LA. (2014) Activating transcription factor 4 (ATF4) modulates post-synaptic development and dendritic spine morphology. Frontiers in cellular neuroscience. 8:177. doi: 10.3389/fncel.2014.00177.

Sproul AA, Vensand LB, Dusenberry CR, Jacob S, Vonsattel JP, Paull DJ, Shelanski ML, Crary JF, Noggle SA. (2014) Generation of iPSC lines from archived non-cryoprotected biobanked dura mater. Acta Neuropathol Commun. 2:4. doi: 10.1186/2051-5960-2-4.

Poon WW, Carlos AJ, Aguilar BL, Berchtold NC, Kawano CK, Zograbyan V, Yaopruke T, Shelanski M, Cotman CW. (2013) β-Amyloid (Aβ) oligomers impair brain-derived neurotrophic factor retrograde trafficking by down-regulating ubiquitin C-terminal hydrolase, UCH-L1. J Biol Chem. 288:16937-48.

Pozueta J, Lefort R, Ribe EM, Troy CM, Arancio O, Shelanski M. (2013) Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice. Nat Commun. 4:1939.

Zou, F et al. (2012) Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants PLoS Genet. 8(6):e1002707 doi: 10.1371/journal.pgen.1002707.

Lefort R, Pozueta J, shelandki M (2012) Cross-linking of cell surface amyloid precursor protein leads to increased β-amyloid peptide production in hippocampal neurons: implications for Alzheimer's disease. J. Neurosci. 32:10674-85.

Malagelada C, López-Toledano MA, Willett RT, Jin ZH, Shelanski ML, Greene LA (2011) RTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migration J Neurosci. 3:3186-96.

Naj AC, et al. (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease Nat Genet. 43:436-41.